What is the recommended dosing and monitoring strategy for bupropion (sustained‑release) as an antidepressant in a male patient with cardiomyopathy and heart failure?

Bupropion Use in Men with Cardiomyopathy and Heart Failure

Bupropion sustained-release can be used cautiously in men with cardiomyopathy and heart failure, starting at 150 mg once daily in the morning with close monitoring of blood pressure, as it has a favorable cardiovascular safety profile compared to tricyclic antidepressants but may cause supine hypertension.

Dosing Strategy

Initial Dosing

• Start with 150 mg sustained-release once daily in the morning 1
• Take with or without food
• Swallow whole—do not crush, divide, or chew 1

Titration Schedule

• After 4-7 days at 150 mg, may increase to 300 mg daily (150 mg twice daily for SR formulation) 1
• The second dose should be taken before 3 PM to minimize insomnia risk 2
• Maximum dose: 300 mg/day in divided doses 2, 1

Special Considerations for Heart Failure Patients

In patients with renal impairment (common in heart failure):

• Consider reducing dose and/or frequency if GFR <90 mL/min 1
• This is critical as heart failure patients often have compromised renal function

In patients with hepatic impairment:

• Mild impairment: Consider dose reduction 1
• Moderate-to-severe impairment: Maximum 150 mg every other day 1

Cardiovascular Safety Profile

Evidence Supporting Use in Cardiac Disease

The cardiovascular profile of bupropion is notably safer than tricyclic antidepressants in cardiac patients. A key study of 36 depressed inpatients with preexisting left ventricular impairment, ventricular arrhythmias, and/or conduction disease found that bupropion (mean dose 442 mg/day) 3:

• Did not cause significant conduction complications
• Did not exacerbate ventricular arrhythmias
• Had a low rate of orthostatic hypotension
• Had no effect on pulse rate

Comparative studies demonstrate bupropion's advantages over tricyclics: it does not increase heart rate (unlike nortriptyline which increased heart rate by 14.5-18 bpm), does not slow cardiac conduction, and causes minimal orthostatic hypotension 4, 5.

Key Cardiovascular Effects to Monitor

Blood Pressure Changes:

• Bupropion causes modest increases in supine blood pressure (5.6-7.5 mmHg diastolic) 4
• This is the primary cardiovascular concern in heart failure patients
• Two patients in the cardiac disease study required discontinuation due to exacerbation of baseline hypertension 3

No significant effects on:

• Heart rate (remains stable) 3, 4
• Cardiac conduction intervals 4
• Ventricular arrhythmias 3
• Orthostatic blood pressure (unlike tricyclics) 4, 5

Monitoring Strategy

Baseline Assessment

• Blood pressure (supine and standing)
• Heart rate
• ECG if conduction disease present
• Renal function (creatinine, GFR)
• Current cardiac medications review

Ongoing Monitoring

Blood pressure monitoring is the critical parameter:

• Check supine and standing BP at baseline, day 7, and day 28 4
• Monitor especially during the first 12 weeks of treatment 6
• More frequent monitoring if baseline hypertension or uncontrolled BP
• Discontinue if uncontrolled hypertension develops 6

Additional monitoring:

• Heart rate at each visit (should remain stable)
• Renal function if dose adjustments needed
• Assess for neuropsychiatric symptoms (depression worsening, suicidal ideation) 1

When to Adjust or Discontinue

• Uncontrolled hypertension: Reduce dose or discontinue 6
• Inadequate response: If <5% improvement in depressive symptoms after 12 weeks at maintenance dose, discontinue 6
• Seizure occurrence: Discontinue immediately (bupropion lowers seizure threshold) 6

Critical Contraindications and Warnings

Absolute Contraindications

• Seizure disorders (bupropion lowers seizure threshold) 7, 6
• Current or recent (within 14 days) MAOI use 1
• Patients requiring chronic opioid therapy (if using naltrexone-bupropion combination) 6

Use with Caution

• Uncontrolled hypertension (should be controlled before initiating) 6
• History of seizures or factors increasing seizure risk 6
• Moderate-to-severe renal or hepatic impairment (requires dose reduction) 1

Drug Interactions in Heart Failure Patients

CYP2D6 Inhibition: Bupropion exhibits dose-dependent CYP2D6 inhibition 8:

• At 150 mg/day: 19% of patients phenoconverted to poor metabolizers
• At ≥300 mg/day: 50% of patients phenoconverted to poor metabolizers

Clinical implications for common cardiac medications:

• Beta-blockers metabolized by CYP2D6 (metoprolol, carvedilol): May require dose reduction due to increased levels
• Monitor for excessive beta-blockade (bradycardia, hypotension)
• Consider therapeutic drug monitoring if available 8

Advantages in This Population

Bupropion may be particularly beneficial for depressed heart failure patients because:

• No weight gain (unlike mirtazapine, paroxetine) 9—important as obesity worsens heart failure
• Activating properties help combat apathy and fatigue common in heart failure 2
• No sexual dysfunction (unlike SSRIs) 9—improves quality of life
• Potential for smoking cessation if patient smokes 7, 6—critical for cardiovascular health

Discontinuation Protocol

When stopping bupropion:

• Taper from 300 mg to 150 mg daily for 1-2 weeks before complete discontinuation 1
• This minimizes withdrawal symptoms
• Abrupt discontinuation should be avoided

Common Pitfalls to Avoid

1. Failing to monitor blood pressure adequately—this is the primary cardiovascular risk
2. Using in patients with uncontrolled hypertension—control BP first
3. Ignoring renal function—heart failure patients often have renal impairment requiring dose adjustment
4. Not accounting for CYP2D6 interactions—particularly important with cardiac medications
5. Dosing too late in the day—causes insomnia; second dose must be before 3 PM 2
6. Crushing or splitting tablets—alters pharmacokinetics and increases seizure risk